CAPTRUST Financial Advisors
EVFM

CAPTRUST Financial Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84
Closed -$1K – 4874
2021
Q2 		$1K Sell
84
-316
-79% -$5.99K ﹤0.01% 4441
2021
Q1 		$11K Buy
+400
New +$18.2K ﹤0.01% 3408

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

CAPTRUST Financial Advisors's EVFM Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 84 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in EVFM in Q1 2021 and held it in 2 quarters. The position peaked at $11K in Q1 2021. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 84 Evofem Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $11K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.